Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Onmark adds EMEND for Injection to portfolio to reduce nausea in chemotherapy patients

Onmark : 23 July, 2008  (Company News)
Onmark has added EMEND for Injection (fosaprepitant dimeglumine) to its contract portfolio, continuing its commitment to ensure access to the latest specialty drugs at competitive pricing.
Developed and marketed by Merck, EMEND is an antiemetic medication that reduces nausea and vomiting for patients receiving chemotherapy.

“The rapid growth in Onmark’s contract portfolio over the past three and a half years reflects our commitment to providing industry-leading value to more than 2,600 member clinics,” said Pat Blake, president of McKesson Specialty.

Onmark serves practices in the community-based treatment setting through its pharmaceutical contract portfolio, which includes brand and generic products that represent the majority of the most widely used chemotherapy, biologic and supportive care agents. In addition, Onmark provides programs and resources designed to help clinics increase efficiencies, lower operating costs and maintain clinical excellence for their patients.

“We are passionate about delivering value to our members through our relationships with leading pharmaceutical and biologics manufacturers,” said Mike Cunningham, PharmD, vice president and general manager of Onmark.

“Through our focus on delivering innovative contracts, Practice management resources, clinical tools and educational programmes, we enable physicians and their staff to run their practices more efficiently and provide the highest quality patient care possible.”

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo